🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Introducing the first cohort of Inova Schar Heart and Vascular and MGH Corrigan Women's Heart Health Program Young Investigator Awards Finalists in Women's CVH! What amazing things you will accomplish! GoRedforWomen AHA Science American College of Cardiology

Huang et al. share their thought provoking study on phenotypes of cardiac dysfunction in breast cancer patients receiving cardiotoxic chemotherapy. Thank you Ana Barac, MD, PhD, FACC, FAHA for the excellent discussions and mentorship.

SOA Expert Panel led by Inova Schar Heart and Vascular Lily N Dastmalchi DO, MA on status of CV clinical competencies in menopause. Suggestions on how to improve research, education, care pathways, health equity in approach to care design. #JACCAdvances June Special Issue jacc.org/doi/10.1016/j.…

#HeartFailure2025 Late-Breaking Science CPETs are increasingly becoming embedded in P2/3 trials of HF and cardiomyopathy. New data support complementary information alongside traditional biomarkers and outcome capture. #MedIQHF2025

Circulation Research Interorgan Crosstalk in #HF & #Cardiometabolic Diseases Compendium CV, #Kidney, #Liver, & Metabolic Interactions in #HF: Breaking Down Silos ahajrnls.org/3ZtHfJQ by Roger Foo Joseph hill Faiez ZANNAD Shahzeb Khan Jennifer Ho Leah Kosyakovsky et al

Pleased to share our review on Multiorgan Imaging in Cardiometabolic Diseases in Circulation. Grateful to our team of imaging experts for their valuable contributions EACVI President Eike Nagel Borja Ibanez Ladislav Valkovic Ana Devesa ahajournals.org/doi/10.1161/CI… University of Oxford NIHR Oxford Biomedical Research Centre

🚨The iCardio Global Guidelines for #Obesity are open for public peer review Please feel free to comment on how these can be improved to apply to the global🌍 community #cardiotwitter #ObesityMedicine 📎icardioalliance.org/public-reviews/

HFpEF is rising—especially in older women—due to unique sex-based risk factors, remodeling patterns, and hormonal influences. This review explores female-predominant phenotypes, sex differences in symptoms and outcomes, and gaps in the literature (link.springer.com/article/10.100…). #HREV

Among 889 with colon cancer s/p resection & adjuvant chemotherapy, RCT shows that a 3y structured exercise program vs health education alone showed 28% relative improvement in disease-free survival at 7.9y nejm.org/doi/full/10.10… NEJM (coverage nytimes.com/2025/06/01/wel…

New in #JACCHF JACC Journals, in-hospital exercise-based cardiac rehab for pts admitted with #ADHF ➡️improvement in 6MWD, QoL, strength, & cognitive function without compromising safety. Early exercise/rehab FTW! 👀: jacc.org/doi/10.1016/j.… Editorial: jacc.org/doi/10.1016/j.…

Enjoying Dr. Meagan Murphy Wasfy's talk on CPET Interpretation? Don’t miss this insightful review she co-authored in #JACC. It offers practical guidance for integrating 📊 from consumer wearable devices into CV clinical care. 🔗 bit.ly/3FSjLYk #ACCAthleticHeart JACC Journals

A 🆕️ ACC Scientific Statement addresses the management of obesity in adults with #HeartFailure, with a specific focus on those with stage 2 HF with #HFpEF. Read more: bit.ly/4n0Fluh #JACC JACC Journals

☝️Must-read for lipidologists and cardiometabolic specialists This new State-of-the-Art Review in JACC outlines the future of triglyceride-lowering therapy beyond statins. 👉ApoCIII, ANGPTL3/4 inhibitors and FGF-21 analogues show powerful effects in reducing triglycerides and

📢 Hot off the press in Journal of Clinical Lipidology: LDL-C management just got clearer: “Lower for longer is better.” This new guidance from the National Lipid Association brings no-nonsense, risk-based recommendations for real-world practice. ✅ LDL-C is causal ✅ Lowering it reduces events

I am thrilled to share our American College of Cardiology Expert Consensus Statement and Concise Clinical Guidance on Medical #WeightManagement ⭐️ jacc.org/doi/10.1016/j.… Special highlights: 👉GLP1 is just the beginning. Myriads of gut hormone permutations necessitate broader acceptance of the

Obesity drives a unique, early-onset form of HFpEF—often underdiagnosed. Yet, no guidelines recommend screening. This review outlines why systematic screening in obesity is overdue and proposes a tailored approach (link.springer.com/article/10.100…). #HREV Josephine Harrington, MD Marat Fudim, MD MHS

Special #JACCAdvances Issue on Prevention Inova Schar Heart and Vascular authors: Lily N Dastmalchi DO, MA jacc.org/doi/10.1016/j.… JaredSpitzMD jacc.org/doi/10.1016/j.… JaredSpitzMD Olayinka J. Agboola jacc.org/doi/10.1016/j.… JaredSpitzMD Garima Sharma M.D jacc.org/doi/10.1016/j.…

So incredibly proud to get to lead this expert panel in #JACCAdvances on lipid management in a post-statin era. We review guidelines, provide recommendations, and offer 🔥case-based discussions. jacc.org/doi/10.1016/j.…

New in AJPC by the Ciccarone team and colleagues; Burka, Aneni, Leucker & Blaha; a paradigm-shifting proposal reshaping the future of ACC/AHA cholesterol and prevention guidelines ow.ly/TlQb50WhhuB 🔄 Reframes 2022 ACC/ECDP Fig. 6 📉 LDL-C targets tied to CAC burden

Review by JaredSpitzMD Garima Sharma M.D, et al in Curr Cardiol Rep traces evolution of ASCVD risk prediction tools, discusses PREVENT, and explores implications of new data regarding preventive therapy Christopher O'Connor link.springer.com/article/10.100…